In hormone-dependent cancers such as breast or prostate cancer, early evidence suggested that HDAC inhibition affects the expression of hormone receptors such as the estrogen receptor (ERα, ERβ) and the progesterone receptor (PR), as well as the androgen receptor (AR). The gene discussed is NR4A1; the disease is prostate carcinoma.